RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
18 Outubro 2023 - 8:00AM
RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical
company developing an innovative pipeline against validated solid
tumor targets, today announced that it will be presenting interim
safety and efficacy data from the Phase 1b portion of the ACTION-1
Trial for RYZ101 (Ac225 DOTATATE) at the upcoming European Society
of Medical Oncology (ESMO) Congress, being held in Madrid between
20-24 October 2023. The poster will be made available in the
“Posters & Presentations” section of the RayzeBio website
at Rayzebio.com/pipeline/posters-presentations following the
presentation.
Title: Poster 1198P: Phase 1b
portion of the ACTION-1 phase 1b/3 trial of RYZ101 in
gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing
after 177Lu somatostatin analogue (SSA) therapy: safety and
efficacy findingsPresenter: Jonathan Strosberg,
M.D.Onsite Poster Display Date: Sunday, October
22, 2023
About RYZ101RYZ101 is an investigational
targeted radiopharmaceutical therapy, designed to deliver a highly
potent radioisotope, Actinium-225 (Ac225), to tumors expressing
SSTR2. RYZ101 is being evaluated in clinical studies for patients
with SSTR+ GEP-NETs who have previously been treated with
Lu177-based somatostatin therapies and also in patients with
extensive stage small cell lung cancer. Details of the studies can
be found at https://clinicaltrials.gov/ct2/show/NCT05477576 and
https://clinicaltrials.gov/ct2/show/NCT05595460.
Ac225 for the study was provided by multiple sources including
the U.S. Department of Energy Isotope Program.
About RayzeBioRayzeBio is building a vertically
integrated radiopharmaceutical therapeutics (RPT) company to treat
various cancers, with its lead program in a Phase 3 clinical trial.
RayzeBio has created a pipeline of multiple drug candidates in
therapeutic areas with significant market opportunities. Much like
antibody drug conjugates emerged as a new and transformative
treatment modality in certain cancers, the company sees an
opportunity for innovative radiopharmaceutical therapeutics to
follow a similar path. RayzeBio believes its strategic investments
in building a robust product pipeline, development capabilities,
and manufacturing infrastructure position the company to be an
industry-leading pioneer in the broad application of RPT for
cancer.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not statements of historical fact are
forward-looking statements. Such forward-looking statements
include, without limitation, statements regarding the potential
benefits of RYZ101 based on the interim safety and efficacy results
of the Phase 1b portion of the ACTION-1 Trial. Words such as
“believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,”
“goal,” “potential” and similar expressions are intended to
identify forward-looking statements, though not all forward-looking
statements necessarily contain these identifying words. These
forward-looking statements are based on the beliefs of the
management of the Company as well as assumptions made by and
information currently available to the Company. Such statements
reflect the current views of the Company with respect to future
events and are subject to known and unknown risks and
uncertainties, including business, regulatory, economic and
competitive risks and uncertainties about the Company, including,
without limitation, risks inherent in developing drug candidates,
future results from the Company’s ongoing and planned clinical
trials, the Company’s ability to obtain adequate financing to fund
its planned clinical trials and other expenses, risks that future
clinical trial results may not be consistent with interim, initial
or preliminary results or results from prior preclinical studies or
clinical trials, trends in the industry, the legal and regulatory
framework for the industry and future expenditures. In light of
these risks and uncertainties, the events or circumstances referred
to in the forward-looking statements may not occur. The actual
results may vary from the anticipated results and the variations
may be material. Other factors that may cause the Company’s actual
results to differ from current expectations are discussed in the
Company’s filings with the Securities and Exchange Commission (the
“SEC”), including the section titled “Risk Factors” in the
Company’s Registration Statement on Form S-1 filed with the SEC on
September 11, 2023. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date this press release is given. Except as required by law, the
Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Arvind KushEmail: info@rayzebio.com
RayzeBio (NASDAQ:RYZB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
RayzeBio (NASDAQ:RYZB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024